Leal Dalila Pinheiro, Gonçalinho Gustavo Henrique Ferreira, Tavoni Thauany Martins, Kuwabara Karen Lika, Paccanaro Ana Paula, Freitas Fatima Rodrigues, Strunz Célia Maria Cassaro, César Luiz Antonio Machado, Maranhão Raul Cavalcante, Mansur Antonio de Padua
Faculdade de Medicina da Universidade de São Paulo, University of São Paulo, Sao Paulo 05508-060, Brazil.
Servico de Prevencao, Cardiopatia da Mulher e Reabilitacao Cardiovascular, Instituto do Coracao do Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (InCor-HCFMUSP), Sao Paulo 05403-900, Brazil.
Antioxidants (Basel). 2022 Nov 29;11(12):2363. doi: 10.3390/antiox11122363.
HDL function has gained prominence in the literature as there is a greater predictive capacity for risk in early coronary artery disease when compared to the traditional parameters. However, it is unclear how dietary energy restriction and atorvastatin influence HDL function.
A randomized controlled trial with 39 women with early CAD divided into three groups (n = 13): energy restriction (30% of VET), atorvastatin (80 mg), and control. Analyses of traditional biochemical markers (lipid and glucose profile), circulating Sirt-1, and HDL function (lipid composition, lipid transfer, and antioxidant capacity).
Participants' mean age was 50.5 ± 3.8 years. Energy restriction increased Sirt-1 by 63.6 pg/mL (95%CI: 1.5-125.7; = 0.045) and reduced BMI by 0.8 kg/m (95%CI: -1.349--0.273; = 0.004) in a manner independent of other cardiometabolic factors. Atorvastatin reduced LDL-c by 40.0 mg/dL (95%CI: -69.910--10.1; = 0.010). Increased Sirt-1 and reduced BMI were independently associated with reduced phospholipid composition of HDL (respectively, β = -0.071; CI95%:-0.136--0.006; = 0.033; β = 7.486; CI95%:0.350-14.622; = 0.040). Reduction in BMI was associated with lower HDL-free cholesterol (β = 0.818; CI95%:0.044-1.593; = 0.039). LDL-c reduction by statins was associated with reduced maximal lipid peroxide production rate of HDL (β = 0.002; CI95%:0.000-0.003; = 0.022) and total conjugated diene generation (β = 0.001; CI95%:0.000-0.001; = 0.029).
This study showed that energy restriction and atorvastatin administration were associated with changes in lipid profile, serum Sirt-1 concentrations, and HDL function.
高密度脂蛋白(HDL)的功能在文献中备受关注,因为与传统参数相比,它对早期冠状动脉疾病风险具有更强的预测能力。然而,目前尚不清楚饮食能量限制和阿托伐他汀如何影响HDL功能。
一项随机对照试验,纳入39例早期冠心病女性患者,分为三组(每组n = 13):能量限制组(占基础能量消耗的30%)、阿托伐他汀组(80毫克)和对照组。分析传统生化指标(血脂和血糖谱)、循环中的沉默信息调节因子1(Sirt-1)以及HDL功能(脂质组成、脂质转运和抗氧化能力)。
参与者的平均年龄为50.5±3.8岁。能量限制使Sirt-1升高63.6 pg/mL(95%置信区间:1.5 - 125.7;P = 0.045),并使体重指数(BMI)降低0.8 kg/m²(95%置信区间:-1.349 - -0.273;P = 0.004),且独立于其他心血管代谢因素。阿托伐他汀使低密度脂蛋白胆固醇(LDL-c)降低40.0 mg/dL(95%置信区间:-69.910 - -10.1;P = 0.010)。Sirt-1升高和BMI降低分别独立与HDL磷脂组成减少相关(β = -0.071;95%置信区间:-0.136 - -0.006;P = 0.033;β = 7.486;95%置信区间:0.350 - 14.622;P = 0.040)。BMI降低与HDL游离胆固醇降低相关(β = 0.818;95%置信区间:0.044 - 1.593;P = 0.039)。他汀类药物降低LDL-c与HDL最大脂质过氧化物生成率降低相关(β = 0.002;95%置信区间:0.000 - 0.003;P = 0.022)以及总共轭二烯生成降低相关(β = 0.001;95%置信区间:0.000 - 0.001;P = 0.029)。
本研究表明,能量限制和阿托伐他汀治疗与血脂谱、血清Sirt-1浓度及HDL功能的变化相关。